148331-73-1Relevant academic research and scientific papers
N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: K(ATP) potassium channel openers. Modifications on the western region
Ohnmacht, Cyrus J.,Russell, Keith,Empfield, James R.,Frank, Cathy A.,Gibson, Keith H.,Mayhugh, Daniel R.,McLaren, Frances M.,Shapiro, Howard S.,Brown, Frederick J.,Trainor, Diane A.,Ceccarelli, Christopher,Lin, Margaret M.,Masek, Brian B.,Forst, Janet M.,Harris, Robert J.,Hulsizer, James M.,Lewis, Joseph J.,Silverman, Stuart M.,Smith, Reed W.,Warwick, Paul J.,Kau, Sen T.,Chun, Alexa L.,Grant, Thomas L.,Howe, Burton B.,Li, Jack H.,Trivedi, Shephali,Halterman, Tracy J.,Yochim, Christopher,Dyroff, Martin C.,Kirkland,Neilson, Kathleen L.
, p. 4592 - 4601 (2007/10/03)
A subset of antiandrogen compounds, the N-aryl-3,3,3-trifluoro-2- hydroxy-2-methylpropanamides 1, were found to activate ATP sensitive potassium channels (K(ATP)) and represent a new class of potassium channel openers (PCOs). A structure-activity relation
Therapeutic amides
-
, (2008/06/13)
Amides having formula I: STR1 wherein E, X, R2 and R3 have the meanings given in the specification, and pharmaceutically acceptable salts and pharmaceutically acceptable in vivo hydrolysable esters thereof, which are useful in the treatment of urinary incontinence. Further provided are processes for preparing the amides and pharmaceutical compositions containing them.
